AMBAR Therapeutic plasma exchange

AMBAR is an innovative clinical trial aimed at slowing down the progression of Alzheimer’s disease through periodic therapeutic plasma exchange.

AMBAR targets a multimodal approach to the management of the disease based on the hypothesis that most of the amyloid-beta protein is bound to albumin and circulates in plasma. Extracting this plasma may flush amyloid-beta peptide from the brain into the plasma, thus potentially limiting the disease’s impact on the patient’s cognitive functions. Additionally, albumin has binding capacity and antioxidant properties, and both albumin and immunoglobulin display immunomodulatory and anti-inflammatory properties.

Based on this hypothesis, the build-up of beta-amyloid could be reduced before it can cause neuronal damage, thus potentially limiting the impact of Alzheimer’s disease on cognition.

LEARN MORE: Grifols

Photoaging

Abstract

Photoaging, also known as extrinsic aging, consists of premature skin changes secondary to damage caused by chronic sun exposure. This review highlights epidemiology, pathogenesis, clinical, and pathological features of photoaging.

UV radiation is the central driver of photoaging. However, there is growing evidence that other environmental factors—including ambient air pollution and visible/infrared light—also play a key role. Furthermore, newer research suggests that skin phototype, ethnicity, and sex can all differentially mediate the process of photoaging.

UV radiation is the primary cause of photoaging, an extrinsic aging of the skin. This process can be exacerbated by other factors including air pollution, visible/infrared light, and endocrine factors. Clinically, decreased skin elasticity (solar elastosis) with wrinkle formation is a characteristic feature. However, differences in the features and timing of presentation may vary by skin phototype, ethnicity, and sex. Prevention through minimizing solar irradiation is key.

SOURCE: Current Dermatology Reports

Infinity Screening System Platform

The Infinity Screening System is a flexible, scalable, high-throughput microfluidic platform.

NemaLife created a future-proof life sciences platform by combining the top-notch technologies of our age, harnessing microfluidics, lab automation, machine learning aided image analysis, and data intelligence.

C. elegans is an established model organism for biological research, disease modeling, and drug discovery. NemaLife knows how laborious it can be to conduct whole-life assays and screening with C. elegans. Relying on our in-house microfluidics fabrication plant with funding from NIH, NSF, and NASA, we developed our patented core technology that offers unique benefits compared to agar, microplate, and even other microfluidics-based technologies.

LEARN MORE: NemaLife

iSense Smart Pillow

The sleep tracker is discretely tucked into the center of the pillow so you won’t feel it or worry about disturbing it in your sleep. Built-in sensors connect to the iPhone app that tracks your heart rate, respiratory rate, sleep cycles, times you turn over, and overall sleep score. Gentle sounds to lull you to sleep. Set your wakeup window and the alarm will gently rouse you at the lightest time in your sleep cycle so you feel refreshed instead of groggy.

Personal biobanking @ GoodCell

Using your own cells, we can identify, track and respond to your health information in an actionable way over time. You create your account in The GoodCell Dashboard, schedule a blood-draw and the sample will be safely packaged to ship for processing.

Once received at GoodCell’s state-of-the-art, FDA-registered CLIA/CAP certified lab and biorepository, we isolate and preserve three components of the blood sample: cells, DNA and blood plasma. Your sample is tested to inform genetic predisposition and additional blood testing is completed.

LEARN MORE: GoodCell

[ sponsored ]